{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:09:02Z","timestamp":1791950942865,"version":"4.3.4"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T00:00:00Z","timestamp":1435190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009996","name":"Sigma-Tau","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite having been long regarded as too toxic for adult patients, pediatric\u2010like regimens containing L\u2010asparaginase have resulted in improved outcomes for adults with acute lymphoblastic leukemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). To characterize the spectrum of toxicity of repeated doses of polyethylene glycolated\u2010asparaginase (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010asp) in adults, we reviewed all doses (2000 <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/m<jats:sup>2<\/jats:sup>) administered as part of a pediatric\u2010inspired regimen in adult <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> at our center. Subjects aged 18\u201360\u00a0yr with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a0152, 69.1% male) contributed 522 dose cycles to the study. Hepatotoxicity was the most common adverse event: grades 3\u20134 transaminitis and hyperbilirubinemia occurred in 53.9% and 23.7% of subjects, respectively. Hepatotoxicity was reversible; no cases of fulminate hepatic failure were observed. Other toxicities affecting at least 5% of subjects were grades 3\u20134 triglyceridemia in 50.9%, hypofibrinogenemia (&lt;100\u00a0mg\/dL) in 47.9%, clinical pancreatitis in 12.6%, venous thromboembolism in 11.2%, allergic reaction in 7.2%, and any grade bleeding in 5.3%. <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010asp was always discontinued after grades 3\u20134 pancreatitis or allergic reaction. Otherwise, toxicities did not preclude administration of additional cycles of the drug. Our results suggest that repeated <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010asp dosing is safe in adults aged 18\u201360\u00a0yr, even after occurrence of a drug\u2010related toxicity.<\/jats:p>","DOI":"10.1111\/ejh.12600","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T15:08:05Z","timestamp":1434726485000},"page":"375-380","source":"Crossref","is-referenced-by-count":81,"title":["Toxicity profile of repeated doses of <scp>PEG<\/scp>\u2010asparaginase incorporated into a pediatric\u2010type regimen for adult acute lymphoblastic leukemia"],"prefix":"10.1111","volume":"96","author":[{"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[{"name":"Leukemia Service Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn E.","family":"Behrendt","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Department of Information Sciences City of Hope National Medical Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Jane Ann Nohl Division of Hematology University of Southern California Keck School of Medicine Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mohrbacher","sequence":"additional","affiliation":[{"name":"Jane Ann Nohl Division of Hematology University of Southern California Keck School of Medicine Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Vrona","sequence":"additional","affiliation":[{"name":"Jane Ann Nohl Division of Hematology University of Southern California Keck School of Medicine Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_2_6_4_1","first-page":"2423","article-title":"Asparaginases. biochemical pharmacology and modes of drug resistance","volume":"32","author":"Avramis VI","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55\u00a0years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer D","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00778.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12948"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231084"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-42647"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353402"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20426"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i5.274"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000095827"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00080.2013"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.109413"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12600","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:45:54Z","timestamp":1696290354000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,25]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/ejh.12600"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12600","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,25]]}}}